 Effect daily etidronate osteolysis multiple myeloma Progressive bone disease multiple myeloma bone resorption pathologic fractures vertebral compression hypercalcemia double-blind study multiple myeloma patients etidronate disodium EHDP diphosphonate compound bone resorption osteoclastic activity patients oral EHDP mg/kg/d placebo death discontinuation due extent vertebral deformity vertebral index height frequency pathologic fractures hypercalcemia bone pain size number osteolytic lesions patients melphalan prednisone daily days weeks primary chemotherapy disease repeated measures analysis significant height loss difference treatment arms significant difference bone pain episodes hypercalcemia development pathologic fractures Patients EHDP deterioration vertebral index difference statistical significance EHDP therapy dosage schedule significant impact multiple myeloma